BiotechTube

Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone

Phase 2Active
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

May 25, 2018 → Nov 15, 2031

NCT ID
NCT03289299

About Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone

Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone is a phase 2 stage product being developed by Amgen for Smoldering Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT03289299. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03289299Phase 2Active

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
52
BHQ880NovartisPhase 2
52
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
51
DenosumabAmgenPhase 2
51
ElranatamabPfizerPhase 2
51
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
51
LinvoseltamabRegeneron PharmaceuticalsPhase 2
51
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
76
SelinexorKaryopharm TherapeuticsPhase 2
44
IPH2101Innate PharmaPhase 2
44
PD-L1 peptideIO BiotechPhase 2
44

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84